The Alzheimer’s Disease Neuroimaging Initiative 4 (ADNI 4) is a non-treatment clinical research study that seeks to discover, optimize, standardize, and validate clinical trial measures and biomarkers used in ongoing AD research. ADNI 4 is the latest phase of the initiative to provide researchers throughout the world access to ADNI data with the belief that open source is the best way to approach Alzheimer’s. In this historic study of brain aging, data from ADNI will help determine the best measures for diagnosis and disease monitoring, which will be used to accelerate the testing of therapeutic interventions and, ultimately, improve Alzheimer’s disease prevention and care.
Who can participate?
- Adults aged 55-90 (inclusive)
- Have either:
- Normal Memory
- Mild Cognitive Impairment*, or
- Dementia*
- Have a Study Partner
- Are willing to commit to the study for five years
- Are available for in-person visits with some virtual options
*Diagnosis is not required (testing is part of study screening)
What would I have to do?
- Individuals must be willing to have MRI and PET scans.
- Screening visit performed by study site staff, which will include various medical assessments and procedures. The screening process may take several weeks to complete.
- Once eligibility is confirmed, participants will come on site for research visits. The frequency of the visits depends on the group assignment (On-site research visits occurring either annually or every other year).
- Brief phone check-ins every six months.
Compensation
Participants will be reimbursed for their time and travel throughout the duration of the study.
Click here for a printable flyer about this study
Contact:
For more information and to sign up for the ADNI 4 Study, please contact ADNI4study@pennmedicine.upenn.edu